Hiroyuki Okuzawa

Daiichi Sankyo's flagship oncology products are growing strongly, with one expected to reach nearly 1 trillion yen in annual sales and another above 100 billion yen. Despite conservative guidance, the fundamental business is robust and will drive continued growth over the next five years.